Wellington Management Group LLP Buys Shares of 59,608 Actinium Pharmaceuticals, Inc. (NYSE:ATNM)

Wellington Management Group LLP bought a new stake in shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) in the 3rd quarter, Holdings Channel.com reports. The institutional investor bought 59,608 shares of the company’s stock, valued at approximately $112,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Los Angeles Capital Management LLC bought a new stake in Actinium Pharmaceuticals in the 3rd quarter valued at about $322,000. Marshall Wace LLP increased its stake in shares of Actinium Pharmaceuticals by 67.9% in the second quarter. Marshall Wace LLP now owns 256,026 shares of the company’s stock valued at $1,895,000 after purchasing an additional 103,557 shares during the period. Squarepoint Ops LLC bought a new stake in shares of Actinium Pharmaceuticals during the second quarter valued at approximately $356,000. Creative Financial Designs Inc. ADV boosted its position in shares of Actinium Pharmaceuticals by 183.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 63,785 shares of the company’s stock worth $120,000 after buying an additional 41,250 shares during the period. Finally, Interchange Capital Partners LLC acquired a new position in shares of Actinium Pharmaceuticals during the third quarter worth approximately $37,000. 27.50% of the stock is currently owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Trading Up 15.2 %

Shares of ATNM stock opened at $1.29 on Friday. The firm has a market cap of $40.24 million, a PE ratio of -0.93 and a beta of 0.07. The firm’s fifty day moving average price is $1.56. Actinium Pharmaceuticals, Inc. has a 1 year low of $1.10 and a 1 year high of $10.24.

Wall Street Analyst Weigh In

ATNM has been the topic of several analyst reports. Stephens restated an “overweight” rating and issued a $5.00 target price on shares of Actinium Pharmaceuticals in a research report on Tuesday, November 19th. HC Wainwright restated a “buy” rating and set a $4.00 price objective on shares of Actinium Pharmaceuticals in a research note on Friday, November 15th. Finally, StockNews.com downgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. According to MarketBeat, Actinium Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $7.40.

Actinium Pharmaceuticals Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).